Quick Answer
REGENERON PHARMACEUTICALS, INC. reported Total Revenue of $14.34 billion for fiscal year 2025.
REGENERON PHARMACEUTICALS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $14.34B +1.0% |
$14.20B +8.3% |
$13.12B +7.8% |
$12.17B -24.3% |
$16.07B +89.1% |
$8.50B +29.6% |
| Revenue (ASC 606) | $14.34B +1.0% |
$14.20B +8.3% |
$13.12B +7.8% |
$12.17B -24.3% |
$16.07B +89.1% |
$8.50B +29.6% |
| Net Income | $4.50B +2.1% |
$4.41B +11.6% |
$3.95B -8.9% |
$4.34B -46.3% |
$8.08B +129.9% |
$3.51B +66.0% |
| Diluted EPS | $41.48 +8.2% |
$38.34 +10.3% |
$34.77 -9.0% |
$38.22 -46.9% |
$71.97 +135.8% |
$30.52 +65.3% |
| Total Assets | $40.56B +7.4% |
$37.76B +14.1% |
$33.08B +13.2% |
$29.21B +14.9% |
$25.43B +48.2% |
$17.16B +15.9% |
| Cash and Equivalents | $3.12B +25.3% |
$2.49B -8.9% |
$2.73B -12.1% |
$3.11B +7.6% |
$2.89B +31.5% |
$2.19B +35.6% |
| Long-Term Debt | $1.99B +0.1% |
$1.98B +0.1% |
$1.98B +0.1% |
$1.98B +0.1% |
$1.98B +0.1% |
$1.98B |
| Stockholders Equity | $31.26B +6.5% |
$29.35B +13.0% |
$25.97B +14.6% |
$22.66B +20.8% |
$18.77B +70.2% |
$11.03B -0.6% |
| R&D Expense | $5.85B +14.0% |
$5.13B +15.6% |
$4.44B +23.6% |
$3.59B +25.6% |
$2.86B +8.1% |
$2.65B +8.0% |
| Operating Income | $3.58B -10.3% |
$3.99B -1.4% |
$4.05B -14.6% |
$4.74B -47.0% |
$8.95B +150.1% |
$3.58B +61.9% |
| Shares Outstanding | — | — | — | — | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $3.75B | +0.9% | +2.1% |
| Revenue (ASC 606) | September 30, 2025 | $3.75B | +0.9% | +2.1% |
| Net Income | September 30, 2025 | $1.46B | +8.9% | +4.9% |
| Diluted EPS | September 30, 2025 | $13.62 | +18.0% | +6.3% |
| Total Assets | September 30, 2025 | $40.17B | +7.3% | +5.1% |
| Cash and Equivalents | September 30, 2025 | $2.51B | +24.6% | +25.6% |
| Long-Term Debt | September 30, 2025 | $1.99B | +0.1% | +0.0% |
| Stockholders Equity | September 30, 2025 | $30.96B | +5.6% | +3.4% |
| R&D Expense | September 30, 2025 | $1.48B | +16.0% | +3.7% |
| Operating Income | September 30, 2025 | $1.03B | -12.9% | -4.9% |
| Shares Outstanding | September 30, 2012 | 94.41M | +4.4% | -99.9% |
- REGENERON PHARMACEUTICALS, INC. reported Total Revenue of $14.34 billion for fiscal year 2025.
- REGENERON PHARMACEUTICALS, INC. showed an increase of +1.0% in Total Revenue compared to the prior fiscal year.
- REGENERON PHARMACEUTICALS, INC. reported Revenue (ASC 606) of $14.34 billion for fiscal year 2025.
- REGENERON PHARMACEUTICALS, INC. showed an increase of +1.0% in Revenue (ASC 606) compared to the prior fiscal year.
- REGENERON PHARMACEUTICALS, INC. reported Net Income of $4.50 billion for fiscal year 2025.
- REGENERON PHARMACEUTICALS, INC. showed an increase of +2.1% in Net Income compared to the prior fiscal year.
- REGENERON PHARMACEUTICALS, INC. reported Diluted EPS of $41.48 per share for fiscal year 2025.
- REGENERON PHARMACEUTICALS, INC. showed an increase of +8.2% in Diluted EPS compared to the prior fiscal year.
- REGENERON PHARMACEUTICALS, INC. reported Total Assets of $40.56 billion for fiscal year 2025.
- REGENERON PHARMACEUTICALS, INC. showed an increase of +7.4% in Total Assets compared to the prior fiscal year.
- REGENERON PHARMACEUTICALS, INC. reported Cash and Equivalents of $3.12 billion for fiscal year 2025.
- REGENERON PHARMACEUTICALS, INC. showed an increase of +25.3% in Cash and Equivalents compared to the prior fiscal year.
- REGENERON PHARMACEUTICALS, INC. reported Long-Term Debt of $1.99 billion for fiscal year 2025.
- REGENERON PHARMACEUTICALS, INC. showed an increase of +0.1% in Long-Term Debt compared to the prior fiscal year.
- REGENERON PHARMACEUTICALS, INC. reported Stockholders Equity of $31.26 billion for fiscal year 2025.
- REGENERON PHARMACEUTICALS, INC. showed an increase of +6.5% in Stockholders Equity compared to the prior fiscal year.
- REGENERON PHARMACEUTICALS, INC. reported R&D Expense of $5.85 billion for fiscal year 2025.
- REGENERON PHARMACEUTICALS, INC. showed an increase of +14.0% in R&D Expense compared to the prior fiscal year.
- REGENERON PHARMACEUTICALS, INC. reported Operating Income of $3.58 billion for fiscal year 2025.
- REGENERON PHARMACEUTICALS, INC. showed a decrease of -10.3% in Operating Income compared to the prior fiscal year.
- REGENERON PHARMACEUTICALS, INC. reported Shares Outstanding of 90.69 million shares for fiscal year 2011.
- REGENERON PHARMACEUTICALS, INC. showed an increase of +4.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: